Nymox completes enrollment in U.S. Phase 3 NX02-0017 study of NX-1207 Nymox Pharmaceutical announced completion of patient enrollment in the company's pivotal U.S. Phase 3 NX02-0017 study of NX-1207 for BPH. This study is now closed to further enrollment. Top-line results from the large Phase 3 Study are expected in late 2013. Paul Averback MD, CEO of Nymox said, "Our drug development programs for NX-1207 include pivotal studies in the U.S. and Europe, re-injection studies in the U.S., prostate cancer trials, and other clinical and non-clinical research activities. Over 2000 patients have participated to date in NX-1207 trials. Final completion of enrollment in this major pivotal study is an important milestone in the NX-1207 development pathway. We look forward to further milestones as this and other trials are completed and results are reported."
News For NYMX From The Last 14 Days
Check below for free stories on NYMX the last two weeks.
Subscribe for More Information